Use of low doses of oligonucleotides antisense to TGF-beta, VEGF, interleukin-10, c-jun, c-fos or prostaglandin E2 genes in the treatment of tumors

Details for Australian Patent Application No. 2009251023 (hide)

Owner Antisense Pharma GmbH

Inventors Schlingensiepen, Reimar; Schlingensiepen, Karl-Hermann

Agent Davies Collison Cave

Pub. Number AU-B-2009251023

Parent 2006243218

Filing date 17 December 2009

Wipo publication date 14 January 2010

Acceptance publication date 2 February 2012

International Classifications

A61K 31/7125 (2006.01) - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters

A61P 25/00 (2006.01) Drugs for disorders of the nervous system

A61P 35/00 (2006.01) Antineoplastic agents

A61P 37/06 (2006.01) Drugs for immunological or allergic disorders

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

C12N 15/113 (2010.01) Mutation or genetic engineering - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Event Publications

7 January 2010 Complete Application Filed

14 January 2010 Application Open to Public Inspection

  Published as AU-B-2009251023

2 February 2012 Application Accepted

  Published as AU-B-2009251023

31 May 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009251024-Use of low doses of oligonucleotides antisense to TGF-beta, VEGF, interleukin-10, c-jun, c-fos or prostaglandin E2 genes in the treatment of tumors

2009251022-Box for Storing Drill Core Samples